Protara Therapeutics, Inc. Cash and Restricted Cash
Protara Therapeutics, Inc. (TARA) had Cash and Restricted Cash of $17.82 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.82M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $50.40M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.30M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $17.82M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $15.48M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $50.40M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $13.30M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $32.24M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $92.21M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $163.54M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $52.50M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $90.33M 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $52.98M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $40.33M 10-Q · filed 2025-11-10 | |
| 2023-09-30 | $34.51M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $34.72M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $21.78M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $24.87M 10-K · filed 2025-03-05 | |
| 2022-09-30 | $48.24M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $34.56M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $26.18M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $36.47M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $41.49M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $47.58M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $59.00M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $169.39M 10-K · filed 2023-03-08 | |
| 2020-09-30 | $165.96M 10-Q · filed 2021-11-04 | $165.95M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $30.02M 10-Q · filed 2021-08-05 | $30.02M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $36.12M 10-Q · filed 2021-05-06 | $36.12M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $564.00K 10-K · filed 2022-03-09 | $564.12K 10-Q · filed 2020-05-13 |
| 2019-09-30 | $1.70M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $2.74M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | $4.12M 10-Q · filed 2020-05-13 | |
| 2018-12-31 | $5.55M 10-K · filed 2021-03-11 | $5.55M 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |